论文部分内容阅读
Itraconazole(ICZ)是新的口服三氮唑类抗真菌药,它具有广谱的抗菌活性、理想的药代动力学特性、良好的临床疗效。药效学ICZ体外抗菌谱与酮康唑类似包括大多数致病真菌如皮癣菌、曲霉菌、二形真菌、着色芽生菌以及烟曲菌等,但抗菌活性更强。 ICZ治疗实验性真菌病的效果与其体外抗菌活性一致,无论口服或局部给药治疗动物皮癣病有效;豚鼠皮肤念珠菌病、假性动情期大鼠阴道念珠菌病可被治愈;豚鼠烟曲菌病的治疗存活率达80%而对照组动物全部死亡,对家兔烟曲菌病的疗效明显高于两性霉素B和5-FC。
Itraconazole (ICZ) is a new oral triazole-based antifungal agent with broad spectrum antibacterial activity, ideal pharmacokinetic properties and good clinical efficacy. Pharmacodynamics ICZ in vitro antibacterial spectrum and ketoconazole similar to most pathogenic fungi such as dermatophytes, Aspergillus, Aspergillus, colored budding bacteria and Aspergillus fumigatus, but more antibacterial activity. ICZ treatment of experimental fungal disease and its antibacterial activity in vitro consistent with either oral or topical treatment of psoriasis in animals effective; Guinea pig cutaneous candidiasis, pseudo-estrous vaginal candidiasis can be cured; Guinea pig smoke song Mycosis disease treatment survival rate of 80% while the control group of animals all died, the efficacy of rabbit Aspergillus fumigatus was significantly higher than amphotericin B and 5-FC.